Ekso Bionics Holdings, Inc. (EKSO) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Biomerica, Inc.

Ekso Bionics Holdings, Inc.

bioAffinity Technologies, Inc.

Venus Concept, Inc.

Prosomnus, Inc.

Ainos, Inc.

BioRestorative Therapies, Inc.

Predictive Oncology, Inc.

Talis Biomedical Corp.

Nemaura Medical, Inc.

MedAvail Holdings, Inc.

Why is Ekso Bionics Holdings, Inc. ?

Poor long term growth as Operating profit has grown by an annual rate 2.63% of over the last 5 years

Flat results in Jun 25

ROCE(HY) Lowest at -96.44%
DEBTORS TURNOVER RATIO(HY) Lowest at 2.65 times
RAW MATERIAL COST(Y) Grown by 25.73% (YoY)

Risky - Negative EBITDA

The stock is trading risky as compared to its average historical valuations
Over the past year, while the stock has generated a return of -57.71%, its profits have risen by 23.9%

Underperformed the market in the last 1 year

Even though the market (S&P 500) has generated returns of 12.33% in the last 1 year, the stock has hugely underperformed and has generate negative returns of -57.71% returns

Real-Time Research Report

Verdict Report

How much should you sell?

All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Ekso Bionics Holdings, Inc. for you?

High Risk, High Return

Absolute

Risk Adjusted

Volatility

Ekso Bionics Holdings, Inc.

-60.62%

0.21

1455.38%

S&P 500

13.22%

0.61

20.17%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

6.35%

EBIT Growth (5y)

2.63%

EBIT to Interest (avg)

-13.29

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.22

Sales to Capital Employed (avg)

0.85

Tax Ratio

Dividend Payout Ratio

Pledged Shares

Institutional Holding

26.33%

ROCE (avg)

ROE (avg)

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

0.81

EV to EBIT

-0.70

EV to EBITDA

-0.82

EV to Capital Employed

0.75

EV to Sales

0.43

PEG Ratio

Dividend Yield

ROCE (Latest)

-107.41%

ROE (Latest)

-86.08%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

RSI

No Signal

Bullish

Bollinger Bands

Bullish

Bearish

Moving Averages

Bearish (Daily)

KST

Bullish

Mildly Bearish

Dow Theory

No Trend

Mildly Bullish

OBV

No Trend

Mildly Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

7What is working for the Company

OPERATING CASH FLOW(Y)

Highest at USD -9.11 MM

NET PROFIT(HY)

Higher at USD -5.6 MM

EPS(Q)

Highest at USD -1.24

-20What is not working for the Company

ROCE(HY)

Lowest at -96.44%

DEBTORS TURNOVER RATIO(HY)

Lowest at 2.65 times

RAW MATERIAL COST(Y)

Grown by 25.73% (YoY

CASH AND EQV(HY)

Lowest at USD 13.3 MM

INVENTORY TURNOVER RATIO(HY)

Lowest at 1.36 times

NET SALES(Q)

Lowest at USD 2.06 MM

OPERATING PROFIT(Q)

Lowest at USD -3.6 MM

OPERATING PROFIT MARGIN(Q)

Lowest at -174.91 %

Here's what is working for Ekso Bionics Holdings, Inc.

Operating Cash Flow

Highest at USD -9.11 MM and Grown

In each year in the last three years

MOJO Watch

The company has generated higher cash revenues from business operations

Operating Cash Flows (USD MM)

Net Profit

Higher at USD -5.6 MM

than preceding 12 month period ended Jun 2025

MOJO Watch

In the half year the company has already crossed Net Profit of the previous twelve months

Net Profit (USD MM)

EPS

Highest at USD -1.24

in the last five periods

MOJO Watch

Increasing profitability; company has created higher earnings for shareholders

EPS (USD)

Here's what is not working for Ekso Bionics Holdings, Inc.

Net Sales

At USD 2.06 MM has Fallen at -58.44%

Year on Year (YoY)

MOJO Watch

Near term sales trend is extremely negative

Net Sales (USD MM)

Debtors Turnover Ratio

Lowest at 2.65 times and Fallen

In each half year in the last five Semi-Annual periods

MOJO Watch

Company's pace of selling Debtors has slowed

Debtors Turnover Ratio

Net Sales

Lowest at USD 2.06 MM

in the last five periods

MOJO Watch

Near term sales trend is negative

Net Sales (USD MM)

Operating Profit

Lowest at USD -3.6 MM

in the last five periods

MOJO Watch

Near term Operating Profit trend is negative

Operating Profit (USD MM)

Operating Profit Margin

Lowest at -174.91 %

in the last five periods

MOJO Watch

Company's profit margin has deteriorated

Operating Profit to Sales

Cash and Eqv

Lowest at USD 13.3 MM

in the last six Semi-Annual periods

MOJO Watch

Short Term liquidity is deteriorating

Cash and Cash Equivalents

Inventory Turnover Ratio

Lowest at 1.36 times

in the last five Semi-Annual periods

MOJO Watch

Company's pace of selling inventory has slowed

Inventory Turnover Ratio

Raw Material Cost

Grown by 25.73% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin

Raw Material Cost as a percentage of Sales